Innovators are unlikely to sit idle
ALN-2232: Dedicated RNAi program for obesity & weight management (Phase 1 data expected H2 2026) $4.9-$5.3B projected 2026 revenue, fueling aggressive expansion in metabolic and cardiometabolic pipelines 10+ tissue types & 40+ clinical programs targeted by 2030 ~30% of revenues reinvested into R&D, accelerating next-generation metabolic innovation Reinforces obesity's emergence as a foundational pillar of future medicine ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter Todays popular weight-loss drugs (like Wegovy or Zepbound) are GLP-1 agonists
In mouse models and autopsy analysis of AD patients, mitochondrial dysfunction and increased reactive oxygen species enhance A aggregation
The purpose of this paper is to present the case that the difference in profitability between Wellpoints PBM business and other PBM operations stems more from differences in business models than from differences in the efficiency of operations
Consequently, these free radicals want to take the electrons of nearby cells, and in doing so, stabilize themselves
Gut healing receives the most favorable reports